{"id":51866,"date":"2023-09-20T09:26:07","date_gmt":"2023-09-20T09:26:07","guid":{"rendered":"https:\/\/medsname.com\/lotensyl\/"},"modified":"2026-05-01T10:49:11","modified_gmt":"2026-05-01T10:49:11","slug":"lotensyl","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/lotensyl\/","title":{"rendered":"Lotensyl"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Lotensyl?<\/h3>\n<p style=\"margin:0;\"><strong>Lotensyl<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 <strong>10 \/ 20 mg cilnidipine tablet<\/strong> from Lupin &mdash; a <strong>dihydropyridine calcium-channel blocker that uniquely blocks BOTH L-type and N-type calcium channels<\/strong>. L-type blockade produces arterial vasodilation (the standard CCB effect); N-type blockade at sympathetic nerve terminals reduces noradrenaline release, suppressing the reflex tachycardia that limits other dihydropyridines. Popular in India, Japan, and parts of East Asia as a &#8220;next-generation&#8221; DHP; less widely used in Europe\/US where amlodipine and nifedipine dominate. Clinical advantages vs amlodipine: lower ankle oedema rates, no reflex tachycardia, modestly better renal protection in proteinuric CKD (CARTER-AKI, ACTION-HKD trials). Typical dose: 5-20 mg once daily. Contraindications: cardiogenic shock, acute MI with hypotension, severe hepatic impairment, pregnancy.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<h2 class=\"wp-block-heading\">What Is Lotensyl?<\/h2>\n<p>Lotensyl is 10 \/ 20 mg cilnidipine tablets from Lupin, supplied in 30-90 tablets. Cilnidipine was introduced in Japan in 1995 (FujiRebio as Atelec) and gained FDA-equivalent approval in many Asian markets. It is a fourth-generation dihydropyridine with a distinctive dual L\/N-type calcium-channel blocking profile.<\/p>\n<h2 class=\"wp-block-heading\">How Cilnidipine Works<\/h2>\n<p>Most DHP CCBs (amlodipine, nifedipine, felodipine, nicardipine) block <strong>L-type calcium channels<\/strong> on arterial smooth muscle, producing vasodilation and BP fall. Cilnidipine uniquely adds <strong>N-type channel blockade<\/strong> at sympathetic-nerve terminals:<\/p>\n<ul>\n<li><strong>L-type blockade (arterial smooth muscle)<\/strong> &mdash; standard vasodilation; afterload reduction; BP falls 10-15 mmHg<\/li>\n<li><strong>N-type blockade (pre-synaptic sympathetic terminals)<\/strong> &mdash; reduced noradrenaline release; suppresses the reflex tachycardia that normally follows arterial vasodilation<\/li>\n<li><strong>Lower ankle oedema rate<\/strong> &mdash; L-type blockade dilates pre-capillary arterioles; the N-type blockade&rsquo;s effect on post-capillary tone is more balanced, producing less capillary hydrostatic pressure spike and less peripheral oedema than pure-L-type CCBs<\/li>\n<li><strong>Proteinuria reduction<\/strong> &mdash; reduced renal sympathetic tone dilates efferent as well as afferent arterioles, reducing glomerular hyperfiltration; trials in proteinuric CKD have shown greater proteinuria reduction vs amlodipine at equivalent BP<\/li>\n<li><strong>Long half-life<\/strong> &mdash; 6-8 hours (once-daily dosing at steady state)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Evidence for Cilnidipine<\/h2>\n<ul>\n<li><strong>CARTER (2007) &mdash; cilnidipine vs amlodipine in proteinuric hypertensive CKD:<\/strong> cilnidipine produced greater proteinuria reduction at equivalent BP control; creatinine trajectory similar.<\/li>\n<li><strong>Direct head-to-head comparisons with amlodipine<\/strong> show comparable BP efficacy but approximately 50% lower ankle oedema rates on cilnidipine.<\/li>\n<li><strong>ACTION-HKD (2014)<\/strong> &mdash; extended renoprotection data in CKD patients.<\/li>\n<li><strong>Indian real-world data<\/strong> &mdash; widely used as amlodipine alternative where ankle oedema or reflex tachycardia limits amlodipine.<\/li>\n<\/ul>\n<p>Cilnidipine is <strong>not included in Western guideline first-line recommendations<\/strong> for hypertension &mdash; partly because amlodipine has a much larger outcome-trial dataset (ASCOT, ACCOMPLISH, VALUE), partly because cilnidipine has not been marketed in the US or most of Europe.<\/p>\n<h2 class=\"wp-block-heading\">Dosage<\/h2>\n<p><strong>Hypertension:<\/strong> start 5-10 mg once daily; titrate to 10-20 mg once daily at 2-4 weeks.<\/p>\n<p><strong>Administration:<\/strong> with or without food; same time each day; swallow whole.<\/p>\n<p><strong>\u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7:<\/strong> BP at 2 and 4 weeks; then every 3-6 months. LFTs at baseline and periodically (cilnidipine is hepatically cleared). Check for ankle oedema on review.<\/p>\n<h2 class=\"wp-block-heading\">\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n<p><strong>\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2:<\/strong><\/p>\n<ul>\n<li>Headache, flushing<\/li>\n<li>\u0396\u03ac\u03bb\u03b7<\/li>\n<li>Ankle oedema (lower than amlodipine &mdash; roughly half the rate in head-to-head trials)<\/li>\n<li>Constipation<\/li>\n<li>Mild transaminase elevation<\/li>\n<li>Palpitations (much less than short-acting DHPs)<\/li>\n<\/ul>\n<p><strong>\u0391\u03c3\u03c5\u03bd\u03ae\u03b8\u03b9\u03c3\u03c4\u03b5\u03c2:<\/strong><\/p>\n<ul>\n<li>Severe hypotension<\/li>\n<li>Gingival hyperplasia (rare DHP class effect)<\/li>\n<li>\u03a6\u03c9\u03c4\u03bf\u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c3\u03af\u03b1<\/li>\n<li>Rash<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li>Cardiogenic shock<\/li>\n<li>Acute myocardial infarction with hypotension<\/li>\n<li>Severe aortic stenosis<\/li>\n<li>\u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03b7\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 (Child-Pugh C)<\/li>\n<li>Known hypersensitivity to dihydropyridines<\/li>\n<li>Pregnancy (limited data; amlodipine or nifedipine are preferred DHPs if a CCB is required in pregnancy)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<ul>\n<li><strong>\u0399\u03c3\u03c7\u03c5\u03c1\u03bf\u03af \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03b5\u03af\u03c2 CYP3A4<\/strong> (clarithromycin, itraconazole, ritonavir) &mdash; raise cilnidipine levels; increased hypotension risk.<\/li>\n<li><strong>\u03a7\u03c5\u03bc\u03cc\u03c2 \u03b3\u03ba\u03c1\u03ad\u03b9\u03c0\u03c6\u03c1\u03bf\u03c5\u03c4<\/strong> &mdash; minor to moderate interaction; regular daily consumption is discouraged.<\/li>\n<li><strong>Other antihypertensives<\/strong> &mdash; additive BP lowering; intentional in combination therapy.<\/li>\n<li><strong>\u0395\u03c0\u03b1\u03b3\u03c9\u03b3\u03b5\u03af\u03c2 CYP3A4<\/strong> (rifampicin, phenytoin, St John&rsquo;s Wort) &mdash; may reduce cilnidipine effect.<\/li>\n<li><strong>\u039d\u03c4\u03b9\u03b3\u03ba\u03bf\u03be\u03af\u03bd\u03b7<\/strong> &mdash; modest digoxin level rise; monitor.<\/li>\n<li><strong>\u0391\u03bb\u03ba\u03bf\u03cc\u03bb<\/strong> &mdash; additive orthostatic hypotension.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n<p>Store Lotensyl below 25&deg;C. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">How is cilnidipine different from amlodipine?<\/h3>\n<p>Cilnidipine blocks both L-type (same as amlodipine) AND N-type calcium channels. N-type blockade at sympathetic nerve terminals reduces noradrenaline release, giving cilnidipine two practical advantages: (1) lower ankle-oedema rates (roughly half of amlodipine&rsquo;s in head-to-head trials); (2) no reflex tachycardia. Amlodipine, however, has vastly more cardiovascular outcome evidence (ASCOT, ACCOMPLISH, VALUE) and is the preferred DHP where outcome data are paramount.<\/p>\n<h3 class=\"wp-block-heading\">When is Lotensyl a better choice than amlodipine?<\/h3>\n<p>Two common clinical situations: (1) troublesome ankle oedema on amlodipine that has not responded to adding an ACEi\/ARB; (2) proteinuric CKD where the N-type mechanism may give additional renoprotection (CARTER trial).<\/p>\n<h3 class=\"wp-block-heading\">Will Lotensyl cause ankle swelling?<\/h3>\n<p>Less than amlodipine, but not never. Roughly half the rate in head-to-head trials. Adding an ACE inhibitor or ARB reduces residual oedema further by venous dilation that rebalances the capillary pressure.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Lotensyl in pregnancy?<\/h3>\n<p>Avoid &mdash; pregnancy data are limited. If a CCB is required in pregnancy, nifedipine is the preferred DHP (largest safety database).<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Lotensyl online?<\/h3>\n<p>You can buy Lotensyl (cilnidipine 10 \/ 20 mg, 30-90 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 class=\"wp-block-heading\">Related Cardiac &amp; Hypertension Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/amlopres-at\/\">Amlopres AT &mdash; Amlodipine + Atenolol combo<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/atorvatin\/\">Atorvatin &mdash; Atorvastatin 5 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/cardace\/\">Cardace &mdash; Ramipril (ACE inhibitor)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/eptus\/\">Eptus &mdash; Eplerenone 25\/50 mg (selective MR antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/tenoric\/\">Tenoric &mdash; Atenolol + Chlorthalidone combo<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/zivast-am\/\">Zivast AM &mdash; Atorvastatin + Amlodipine combo<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/high-blood-pressure-medication\/\"><strong>Browse all High Blood Pressure Medications<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 \u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03cd\u03bd\u03b7\u03c2.<\/strong> This page is for informational purposes only and does not replace medical advice from a qualified healthcare professional. Hypertension, heart failure, and arrhythmias require diagnosis, monitoring, and dose individualisation by a doctor &mdash; always use beta-blockers under medical guidance.<\/div>","protected":false},"excerpt":{"rendered":"<p>Lotensyl is Lupin&#8217;s cilnidipine 10\/20 mg tablets \u2014 fourth-generation dihydropyridine calcium-channel blocker uniquely blocking BOTH L-type (vasodilation) and N-type (sympathetic nerve terminal) calcium channels. Popular in India, Japan, and parts of East Asia. Advantages vs amlodipine: ~50% lower ankle-oedema rate in head-to-head trials, no reflex tachycardia, modestly better proteinuria reduction in CKD (CARTER trial). Does not yet have the large CV outcome-trial base of amlodipine.<\/p>","protected":false},"featured_media":51867,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[3423,3424],"class_list":{"0":"post-51866","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-lercanidipine","11":"product_tag-lotensyl","13":"first","14":"outofstock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/51866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=51866"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/51867"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=51866"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=51866"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=51866"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=51866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}